Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin, Jinfang Zheng, Sadahisa Ogasawara, Ji Hoon Kim, Haitao Zhao, Chuan Li, David C. Madoff, R. Mark Ghobrial, Tomokazu Kawaoka, René Gerolami, Masafumi Ikeda, Hiromitsu Kumada, Anthony B. El-Khoueiry, Arndt Vogel, Xiang Peng, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Josep M. Llovet